SCHEMBL17799710

SCHEMBL17799710

O=C(N[C@H]1CC[C@H]1c1ccc(Cl)cc1Cl)c1ccccc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ HPGD P15428 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ SLC6A12 P48065 1/20 0.42
▸ P2RX7 Q99572 1/20 0.42
▸ TAS1R3 Q7RTX0 2/20 0.42
▸ TAS1R1 Q7RTX1 2/20 0.42
▸ TAS1R2 Q8TE23 2/20 0.42
▸ HTT P42858 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ MIF P14174 1/20 0.41
▸ F2R P25116 1/20 0.40
▸ PNLIP P16233 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17799743 0.89 SLC6A12 (0.47) NPC1HPGDRAB9ASLC6A12P2RX7
SCHEMBL16372239 0.86 SIGMAR1 (0.45) NPC1RAB9ASLC6A12P2RX7TAS1R3
SCHEMBL17799736 0.86 TAS1R3 (0.49) NPC1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL16372221 0.86 GRM5 (0.52) SMN1; SMN2MEN1KMT2ARAB9AL3MBTL1
SCHEMBL17799749 0.86 SIGMAR1 (0.45) NPC1RAB9ASLC6A12P2RX7TAS1R3
SCHEMBL17799642 0.86 GRM5 (0.52) SMN1; SMN2MEN1KMT2ARAB9AL3MBTL1
SCHEMBL15295033 0.83 HCRTR1 (0.45) TP53SLC6A12P2RX7TAS1R3TAS1R1
SCHEMBL16451641 0.83 HCRTR1 (0.45) TP53SLC6A12P2RX7TAS1R3TAS1R1
SCHEMBL15295032 0.83 HCRTR1 (0.45) TP53SLC6A12P2RX7TAS1R3TAS1R1
SCHEMBL16451640 0.83 HCRTR1 (0.45) TP53SLC6A12P2RX7TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS NPC1 1078/4885SMN1; SMN2 678/4885MEN1 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback